Omeros Corporation (OMER) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity buffer ⢠Cash burn ⢠Weak capital base OMER has strong near-term liquidity and a quarter of reported profit, but its annual losses, negative cash flow, no revenue base, and negative equity point to a fragile, cash-burning financial profile. #cash burnâ
Price Behavior
Key Price Behavior Insights: ⢠Higher-highs trend ⢠Strong recent breakout ⢠Overextension risk Support Level: $12.25â$12.54 Resistance Level: $13.53 OMER has been in a strong uptrend over the last month, but after a steep run to $13.53 it looks extended and may need to hold $12.25â$12.54 to keep momentum intact.
Sentiment & News
Key News Insights: ⢠Profitability rebound ⢠Analyst optimism ⢠CMS billing support Omeros is seeing improving financials, stronger analyst/investor interest, and a key CMS reimbursement win for YARTEMLEA that could accelerate commercialization.
AI Summary
OMER has shifted from a binary approval bet to a launch-stage commercialization story with a permanent CMS J-code and real reimbursement access, but the investment now hinges on whether YARTEMLEA can quickly generate sustained revenue before the company's fragile balance sheet, heavy debt, and one-product concentration become a problem.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |